Description
A dual agonist of PPARα and PPARγ (EC50s = 0.32 and 0.11 μM, respectively); selective for PPARα/γ over other nuclear receptors, including PPARδ, RXRα, RARs, ERα/β, AR, and PR; reduces the size of lipid droplets in oleic acid-treated HepaRG human hepatocytes at 50 μM; reduces plasma levels of glucose, triglycerides, free fatty acids, and insulin by 54, 33, 62, and 48%, respectively, in db/db mice at 10 mg/kg per day; reduces plasma levels of glucose, triglycerides, and cholesterol in diet-induced obese mice at 10 mg/kg per day; inhibits LPS-induced increases in NO production and IL-6, TNF-α, and iNOS protein levels in J774 murine macrophages; inhibits carrageenan-induced paw edema in mice at 12.5-50 mg/kg
Formal name: N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-glycine
Synonyms: BMS-298585
Molecular weight: 516.5
CAS: 331741-94-7
Purity: ≥98%
Formulation: A crystalline powder
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cell Biology|Cell Signaling|Nitric Oxide Signaling||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Immunology & Inflammation|Innate Immunity
